RayKnowChina Research Map
Shortlist

RecruitingBreast cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer

An open trial on breast cancer, registered on ClinicalTrials.gov. Led by Henan Cancer Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorHenan Cancer Hospital河南省肿瘤医院ZhengzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06276868, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to 70 years; sex: women only

    Registered eligibility fields

  2. Pathologically confirmed as invasive breast cancer, with tumor staging of II-IIIA.

    Inclusion criterion 3

  3. For female patients who have not undergone menopause or surgical sterilization: Agree to abstain or use effective contraceptive methods during the treatment period and at least 7 months after the last administration during the study treatment.

    Inclusion criterion 6

  4. ECOG score 0-1 points.

    Inclusion criterion 2

  5. The patient had undergone major surgical procedures unrelated to breast cancer within 4 weeks before enrollment, or the patient has not fully recovered from such surgical procedures.

    Exclusion criterion 5

    Individuals with a known history of allergies to the drug components of this protocol;Having a history of immunodeficiency, including HIV testing positive, or suffering from other acquired or congenital immunodeficiency diseases, or having a history of organ transplantation.

    Exclusion criterion 8

  6. Pregnant and lactating female patients, those with fertility and positive baseline pregnancy test results, or those of childbearing age who are unwilling to take effective contraceptive measures during the entire trial period and within 7 months after the last study medication.

    Exclusion criterion 9

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06276868, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Female initial treatment patients aged ≥ 18 years and ≤ 70 years.
  • ECOG score 0-1 points.
  • Pathologically confirmed as invasive breast cancer, with tumor staging of II-IIIA.
  • HR positive HER-2 positive.
  • The main organs function normally and meet the following standards:

(1)The blood routine examination standards must comply with:ANC ≥1.5×10 9/L;PLT ≥100×109/L;Hb ≥90g/L. (2)Biochemical examination must meet the following standards: TBIL ≤ 1.5 Upper limit of normal value (ULN);ALT and AST ≤ 1.5 times the upper limit of normal value (ULN);Alkaline phosphatase ≤ 2.5 times the upper limit of normal value (ULN);BUN and Cr ≤ 1.5 × ULN and creatinine clearance rate ≥ 50 mL/min; (3)Cardiac ultrasound and echocardiography: Left ventricular ejection fraction (LVEF ≥ 50%).

  • For female patients who have not undergone menopause or surgical sterilization: Agree to abstain or use effective contraceptive methods during the treatment period and at least 7 months after the last administration during the study treatment.
  • Volunteer to join this study and sign an informed consent form.

Exclusion Criteria:

  • Stage IV (metastatic) breast cancer.
  • inflammatory breast cancer.
  • Previously received anti-tumor therapy or radiation therapy for any malignant tumor, excluding cured cervical cancer in situ, basal cell carcinoma, or squamous cell carcinoma.
  • Simultaneously receiving anti-tumor therapies in other clinical trials, including endocrine therapy, bisphosphate therapy, or immunotherapy.
  • The patient had undergone major surgical procedures unrelated to breast cancer within 4 weeks before enrollment, or the patient has not fully recovered from such surgical procedures.
  • Individuals who have previously suffered from clinically significant lung diseases, including but not limited to interstitial pneumonia, pneumonia, pulmonary fibrosis, and radiation pneumonia (excluding radiation changes that do not require corrective treatment), or those who have been found to have such diseases through screening period examinations.
  • Serious heart disease or discomfort, including but not limited to the following diseases:

(1)Confirmed history of heart failure or systolic dysfunction (LVEF<50%). (2)High risk uncontrolled arrhythmia(atrial tachycardia,ventricular tachycardia,Higher level atrioventricular block); (3)Angina pectoris requiring treatment with anti angina drugs; (4)Clinically significant heart valve disease; (5)ECG shows transmural myocardial infarction; (6)Poor control of hypertension (systolic blood pressure>180 mmHg and/or diastolic blood pressure>100 mmHg); 8. Inability to swallow, intestinal obstruction, or other factors that affect drug administration and absorption.

  • Individuals with a known history of allergies to the drug components of this protocol;Having a history of immunodeficiency, including HIV testing positive, or suffering from other acquired or congenital immunodeficiency diseases, or having a history of organ transplantation.
  • Pregnant and lactating female patients, those with fertility and positive baseline pregnancy test results, or those of childbearing age who are unwilling to take effective contraceptive measures during the entire trial period and within 7 months after the last study medication.
  • Suffering from severe comorbidities or other comorbidities that may interfere with the planned treatment, or any other situation where the researcher deems the patient unsuitable to participate in this study.

Quoted from ClinicalTrials.gov, NCT06276868, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06276868, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06276868